علاج السل الصفاقي في السل متعدد مقاومة الأدوية

References

1. Multidrug resistance (MDR) has been observed in 2.4–13.2% of strains of MTB isolated from newly diagnosed pulmonary TB patients and in 17.4–25.5% of previously treated patients.
2. Kanamycin (an injectable agent), moxifloxacin, prothionamide, clofazimine, isoniazid, pyrazinamide and ethambutol, given together in an initial phase of 4 months (with the option of extending to 6 months if the patient is still positive on a sputum smear at the end of month 4).
3. Followed by an intensive phase of 5 months of treatment with four of the medicines (moxifloxacin, clofazimine, pyrazinamide, and ethambutol).
4. Medicines are taken once per day, all days of the week.
5. If the intensive phase is prolonged, the injectable agent is only given three times a week after the fourth month.